Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 14
Oral Semaglutide: A 25-Person Readout
A 25-person Japanese study linked oral semaglutide with lower energy intake, weight and body fat after three months, with key muscle caveats.
Peptide nasal sprays: the safety gap
Why a peptide vial and an empty nasal bottle do not add up to a safe home preparation, and what the Semax evidence can actually tell us.
Semaglutide ASCVD cost model
A US veteran model found lifetime semaglutide added 1.31 QALYs but cost $118,996 per QALY at an assumed $14,000 annual price.
Switching from tirzepatide to retatrutide
No trial has established a tirzepatide-to-retatrutide switching protocol. Retatrutide remains investigational, and separate trial averages are not a guide.
Why GLP-1 Weight Loss Varies
A new meta-analysis finds wide variation in GLP-1 and dual-agonist trial results. Here is what the pooled number can and cannot tell readers.
BPC-157 and TB-500 side effects
What official sources and limited human research can, and cannot, say about a possible reaction after products labelled BPC-157 and TB-500.
Dizziness and poor sleep need context
Dizziness on standing and poor sleep need clinical context, not a new peptide stack or a forum-based treatment plan.
Facial nodules and compounded tirzepatide
One case linked facial nodules to compounded tirzepatide, but missing biopsy and cultures leave inflammation, infection and product factors unresolved.
GLP-1 drugs before surgery: what changed
A 2026 surgical review supports risk-based planning for semaglutide and tirzepatide, but it reports no new trial or aspiration rate.
GLP-1 Mental Health Data in Teens
A small chart review found no short-term increase in suicidality screens among adolescents with obesity using liraglutide or semaglutide.
Incretin weight loss in type 1 diabetes
A 70-person study linked liraglutide, semaglutide, or tirzepatide treatment with fat loss, modest lean loss, and stable total-body bone density.
What a tirzepatide COA cannot verify
A COA may describe a tested sample, but it cannot replace FDA approval, licensed pharmacy dispensing, or individual clinical assessment.